Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results